Charles Schwab
BBOT

Charles Schwab’s BridgeBio Oncology BBOT Stock Holding History

Charles Schwab’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.6M Buy
290,806
+11,760
+4% +$126K ﹤0.01% 2638
2025
Q4 		$3.49M Sell
279,046
-304
-0.1% -$3.68K ﹤0.01% 2586
2025
Q3 		$3.23M Buy
+279,350
New +$2.91M ﹤0.01% 2610

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's BBOT Position: Q1 2026 in Review

Charles Schwab increased its BridgeBio Oncology (BBOT) stake by 4.2% in Q1 2026, buying an estimated $126K and bringing the position to 290,806 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Charles Schwab first reported a position in BBOT in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.49M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Charles Schwab held 290,806 shares of BridgeBio Oncology worth $2.6M as of Q1 2026.
  • Charles Schwab bought 11,760 BridgeBio Oncology shares in Q1 2026, an estimated $126K.
  • BridgeBio Oncology made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2638 holding.
  • Charles Schwab first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 3 quarters since.
  • Charles Schwab's BridgeBio Oncology position peaked at $3.49M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.